

Special Issue

Understanding the Mechanisms behind Cancer Therapy Resistance and Finding Solutions

Message from the Guest Editors

Current cancer research is facing several challenges, including resistance to chemotherapy, radiotherapy, immunotherapy, and molecularly targeted treatments. The mechanisms of resistance to cancer treatments have been found to be selective for molecular targets and in many cases share common resistance strategies. We welcome submissions of original research, systematic reviews, clinical trials, and brief research reports, which explore the role of drug resistance in the context of cancer or identify cutting-edge approaches to combating therapeutic resistance. Potential topics include but are not limited to:

- Mechanisms of resistance for cancer chemotherapy, radiotherapy, targeted therapy, and immunotherapy for solid and hematological malignancies;
- Novel markers of cancer resistance;
- Use of multi-omics as a strategy for deciphering novel cancer drug resistance;
- Innovative approaches to overcoming cancer therapeutic resistance.

Special consideration will be given to new multimodal therapeutic strategies for combating molecular targets linked to multidrug resistance (MDR) and cancer immunotherapies.

Guest Editors

Dr. Carlo Cenciarelli

Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy

Prof. Dr. Hany E. Marei

Faculty of Veterinary Medicine, Department of Cytology and Histology, Mansoura University, Mansoura, Egypt

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/148347

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).